NVO

Novo Nordisk A/S (NVO)

Last Price$88.15.2%
Market Cap$392.3B
LTM Revenue
$42.1B
YoY Growth
+24.9%
3Y CAGR
+23.4%
5Y CAGR
+18.1%
Stock quality & Intrinsic value
7/10
30.9% overvalued

Novo Nordisk A/S Revenue

Annual
Quarterly
LTM
Crunching data... Almost there!
Dec'05Dec'06Dec'07Dec'08Dec'09Dec'10Dec'11Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24
Revenue
$6,381.6M
$6,510.9M
$7,686.0M
$8,987.0M
$9,541.6M
$10.8B
$12.4B
$13.4B
$14.9B
$15.8B
$16.1B
$16.6B
$16.9B
$17.7B
$18.3B
$19.4B
$22.4B
$25.0B
$33.7B
$42.1B
NVO
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for NVO and see if it's the right time to invest.
Dive in

Novo Nordisk A/S (NVO) Revenue comparison analysis

Crunching data... Almost there!

NVO key stats

USD
DKK
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Crunching data... Almost there!

Discover more Stock Ideas

FAQ

1) What is Novo Nordisk A/S's Revenue?

As of today, Novo Nordisk A/S's last 12-month Revenue is $42.1B, based on the financial report for Dec 31, 2024 (Q4 2024).

2) What is Novo Nordisk A/S's Revenue growth rate?

Over the last year, Novo Nordisk A/S's Revenue growth was 24.9%. The average annual Revenue growth rates for Novo Nordisk A/S have been 26.5% over the past three years, 18.1% over the past five years.

3) Is Novo Nordisk A/S's Revenue growth rate Good?

Over the last year, Novo Nordisk A/S's Revenue growth was 24.9%, which is higher than industry growth of 2.7%. It indicates that Novo Nordisk A/S's Revenue growth is Good.

4) How does Novo Nordisk A/S's Revenue growth rate compare to its peers?

Over the last year, Novo Nordisk A/S's Revenue growth was 24.9%, which is lower than peer median growth of 32.8%. The list of peers includes REGN, VRTX, INCY, BGNE, BNTX, UTHR, RPRX, ARGX, ALNY, SMMT etc.